Potential metabolite markers of schizophrenia

Molecular Psychiatry

Volumn 18, Issue 1, 2013, Pages 67-78

  Yang, J ^a,b   Chen, T ^c   Sun, L ^a,b   Zhao, Z ^d   Qi, X ^a   Zhou, K ^a,b   Cao, Y ^c   Wang, X ^c   Qiu, Y ^e   Su, M ^e   Zhao, A ^a   Wang, P ^f   Yang, P ^f   Wu, J ^a   Feng, G ^a,b   He, L ^a,b   Jia, W ^c   Wan, C ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c Shanghai Jiao Tong University   (China)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^f Wuhu No 4 People's Hospital   (China)

Author keywords

biomarker; GC TOFMS; metaobonomics; NMR; schizophrenia

Indexed keywords

3 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; CYSTINE; FATTY ACID; GLYCERIC ACID; KETONE; PYRUVIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PRIORITY JOURNAL; SCHIZOPHRENIA; URINALYSIS;

3-HYDROXYBUTYRIC ACID; ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; CYSTINE; FATTY ACIDS, MONOUNSATURATED; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GLYCERIC ACIDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOME; MIDDLE AGED; PYRUVIC ACID; ROC CURVE; SCHIZOPHRENIA;

EID: 84871291341     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2011.131     Document Type: Article

References (56)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005; 2: e141.
2. Freedman R. Schizophrenia. N Engl J Med 2003; 349: 1738-1749.
3. MacDonald AW, Schulz SC. What we know: findings that every theory of schizophrenia should explain. Schizophr Bull 2009; 35: 493-508.
4. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-928.
5. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.
6. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-799.
7. Horrobin DF. Schizophrenia: A biochemical disorder? Biomedicine 1980; 32: 54-55.
8. Puri BK, Easton T, Das I, Kidane L, Richardson AJ. The niacin skin flush test in schizophrenia: A replication study. Int J Clin Pract 2001; 55: 368-370.
9. Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr Res 2003; 61: 1-6.
10. Bosveld-van Haandel L, Knegtering R, Kluiter H, van den Bosch RJ. Niacin skin flushing in schizophrenic and depressed patients and healthy controls. Psychiatry Res 2006; 143
11. 303-306. 11 Abou-Saleh MT. Neuroimaging in psychiatry: An update. J Psychosom Res 2006; 61: 289-293.
12. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747.
13. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe'er I et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757.
14. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752.
15. Teng PN, Bateman NW, Hood BL, Conrads TP. Advances in proximal fluid proteomics for disease biomarker discovery. J Proteome Res 2010; 9: 6091-6100.
16. Cowan ML, Vera J. Proteomics: Advances in biomarker discovery. Expert Rev Proteomics 2008; 5: 21-23.
17. Kaddurah-Daouk R, Krishnan KR. Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009; 34: 173-186.
18. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181-1189.
19. Zyromski NJ, Mathur A, Gowda GAN, Murphy C, Swartz-Basile DA, Wade TE et al. Nuclear magnetic resonance spectroscopybased metabolomics of the fatty pancreas: implicating fat in pancreatic pathology. Pancreatology 2009; 9: 410-419.
20. Boudonck KJ, Mitchell MW, Ne'met L, Keresztes L, Nyska A, Shinar D et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 2009; 37: 280-292.
21. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
22. Kaddurah-Daouk R, Soares JC, Quinones MP. Metabolomics: A global biochemical approach to the discovery of biomarkers for psychiatric disorders. In: Turck C (ed). Biomarkers for Psychiatric Disorders. Springer: New York, USA, 2009, pp 1-34.
23. Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ et al. Metabolic changes in schizophrenia and human brain evolution. Genome Biol 2008; 9: R124.
24. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 684-697, 643.
25. Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30: 193-208.
26. Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D et al. High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 2008; 7: 4266-4277.
27. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009; 35: 165-176.
28. Huang JT, Leweke FM, Tsang TM, Koethe D, Kranaster L, Gerth CW et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007; 2: e756.
29. Tsang TM, Huang JT, Holmes E, Bahn S. Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res 2006; 5: 756-760.
30. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12: 934-945.
31. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, Montrose DM, MatsonWR et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15: 938-953.
32. Yao JK, Dougherty Jr. GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia. PLoS One 2010; 5: e9508.
33. Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009; 8: 4844-4850.
34. Jonsson P, Gullberg J, Nordstrom A, Kusano M, Kowalczyk M, Sjostrom M et al. A strategy for identifying differences in large series of metabolomic samples analyzed by GC/MS. Anal Chem 2004; 76: 1738-1745.
35. Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, Grung B et al. High-throughput data analysis for detecting and identifying differences between samples in GC/MS-based metabolomic analyses. Anal Chem 2005; 77: 5635-5642.
36. Golland P, Liang F, Mukherjee S, Panchenko D. Permutation tests for classification. In: Auer P, Meir R (eds). Learning Theory, vol. 3559, Springer: Berlin/Heidelberg, 2005, pp 501-515.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser 1995; B57: 12.
38. Bradley AP. The use of the area under the ROC curve in the evaluation of machine learning algorithms. Pattern Recogn 1997; 30: 1145-1159.
39. Sokoloff L. Metabolism of ketone bodies by the brain. Annu Rev Med 1973; 24: 271-280.
40. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Paras L et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 1999; 25: 321-335.
41. Olsen L, Hansen T, Jakobsen KD, Djurovic S, Melle I, Agartz I et al. The estrogen hypothesis of schizophrenia implicates glucose metabolism: Association study in three independent samples. BMC Med Genet 2008; 9: 39.
42. Hazlett EA, Buchsbaum MS, Kemether E, Bloom R, Platholi J, Brickman AM et al. Abnormal glucose metabolism in the mediodorsal nucleus of the thalamus in schizophrenia. Am J Psychiatry 2004; 161: 305-314.
43. Martins-de-Souza D, Harris LW, Guest PC, Bahn S. The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal 2011; 15: 2067-2079.
44. Buchsbaum MS, Hazlett EA. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr Bull 1998; 24: 343-364.
45. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
46. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007; 24: 481-485.
47. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A et al. Metabolic profile of antipsychotic-naïve individuals with non-affective psychosis. Br J Psychiatry 2009; 194: 434-438.
48. Buchsbaum MS, Buchsbaum BR, Hazlett EA, Haznedar MM, Newmark R, Tang CY et al. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry 2007; 164: 1072-1081.
49. Bu B, Ashwood P, Harvey D, King IB, Water JV, Jin LW. Fatty acid compositions of red blood cell phospholipids in children with autism. Prostaglandins Leukot Essent Fatty Acids 2006; 74: 215-221.
50. Apel K, Hirt H. Reactive oxygen species: Metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol 2004; 55: 373-399.
51. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384: 505-516.
52. McBean GJ. Cerebral cystine uptake: A tale of two transporters. Trends Pharmacol Sci 2002; 23: 299-302.
53. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ et al. Alpha-hydroxybutyrate is an early biomarker of insulinresistance and glucose intolerance in a nondiabetic population. PLoS One 2010; 5: e10883.
54. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr 2000; 130(Suppl): 1016S-1022S.
55. McDonald JW, Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res Brain Res Rev 1990; 15: 41-70.
56. Miller AL, Hawkins RA, Veech RL. Decreased rate of glucose utilization by rat brain in vivo after exposure to atmospheres containing high concentrations of CO2. J Neurochem 1975; 25: 553-558.